GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot
Portfolio Pulse from Vandana Singh
GSK plc has reported Q3 FY23 sales of £8.15 billion ($10.26 billion), up 4% Y/Y. Adjusted EPS of 50.4p ($1.27 Adj. EPADS) increased 7% on AER and 17% on CER, beating the Wall Street estimate of $1.07. The company has raised its FY23 sales growth guidance to 12%-13%, up from previous guidance of 8%-10%. Adjusted operating profit is expected to increase 13%-15%, from previous guidance of 11%-13%. GSK expects adjusted earnings per share growth of between 17%-20% versus previous guidance of 14%-17%. However, GSK shares are down 2.27% at $34.89 during the premarket session on the last check Wednesday.
November 01, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
GSK has reported strong Q3 FY23 results, beating Wall Street estimates, and raised its FY23 guidance. However, its shares are down in premarket trading.
Despite reporting strong Q3 results and raising its FY23 guidance, GSK's shares are down in premarket trading. This could be due to a variety of factors, including market sentiment, broader market trends, or investor expectations. However, the strong results and raised guidance could potentially lead to a positive impact on the stock in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100